Even healthy 25-year-old alcohol drinkers were found to have changes in vascular and inflammatory markers: the experiment showed that the reaction is dose-dependent.

Even in young people without diagnosed chronic diseases, increased alcohol consumption is associated with changes in biomarkers involved in the regulation of blood vessels, metabolism, and inflammation. Furthermore, a single dose of alcohol can alter individual signaling molecules over the course of several hours, with the nature of the response depending on the amount consumed. These are the findings of researchers at Brown University in a randomized, placebo-controlled experiment published on September 7, 2026, in Alcohol: Clinical and Experimental Research. [1]

The study involved 32 healthy adults with an average age of 25 years. Fifteen were classified as light drinkers, while 17 were classified as heavy drinkers. Each participant was randomly assigned to three laboratory sessions: a placebo drink, a low-dose alcohol dose of 0.35 g ethanol per kilogram of body weight, and a moderate experimental dose of 0.60 g/kg. For four hours after drinking the drink, the researchers collected hourly blood samples and analyzed ten biomarkers associated with chronic diseases. [2]

The most significant difference was found not after a single experimental alcohol intake, but between groups with different drinking histories. Young participants in the heavier drinking group had higher levels of adiponectin, angiogenin, ICAM-1, lipocalin-2, and the soluble receptor for advanced glycation end products (sRAGE). These molecules are involved in metabolic regulation, vascular endothelial health, and inflammatory signaling. Moreover, the participants were young, generally healthy, and the average duration of heavier alcohol consumption in the corresponding group was only about 1.7 years. [3]

With a single dose, sRAGE showed the most interesting response. After an initial decrease in its concentration, which was also observed with placebo, at a dose of 0.60 g/kg, the indicator increased again within two to three hours. The authors consider this a possible short-term compensatory response of the body to increased oxidative or inflammatory stress. However, the study does not prove that the observed changes already indicate the onset of a specific disease or that a single blood test can predict the future risk of heart attack, diabetes, or dementia. [4]

Key parameter	Result
Type of study	randomized, placebo-controlled, crossover
Participants	32 people
Middle age	25.0 ± 3.8 years
Women	21 of 32
Easy to use	15 people
More intensive use	17 people
Experimental conditions	placebo, 0.35 g/kg, 0.60 g/kg alcohol
Observation	4 hours after drink
Blood collections	initially and every hour
Biomarkers studied	10
Higher in heavier drinkers	adiponectin, angiogenin, ICAM-1, LCN2, sRAGE
Acute dose-dependent signal	sRAGE
hsCRP	lower at the low dose, but the authors do not consider this to be evidence of anti-inflammatory benefit
D-dimer and TREM2	no significant effects were identified
DOI	10.1111/acer.70362

Why did scientists decide to look for changes even before the disease appeared?

For decades, epidemiologists have argued for a so-called J-shaped relationship between alcohol and certain diseases: individuals who consume small amounts of alcohol have been shown in some observational studies to have a lower cardiovascular risk than those who abstain completely. However, more recent studies, with better control for confounding factors and genetic methods for causal analysis, have significantly weakened the arguments for alcohol's protective effect. The authors of the new study argued that even low or moderate exposure can affect multiple biological systems simultaneously. [5]

The problem is that most studies of alcohol and chronic disease are observational. If a person who drinks heavily develops hypertension, liver disease, or atherosclerosis over time, it's difficult to accurately determine how much of the risk is directly related to ethanol and how much is due to diet, smoking, social conditions, baseline health, or other lifestyle factors. Conducting a long-term experiment in which people are randomly assigned to regularly consume large amounts of alcohol is ethically impossible.

Studies with controlled, single-dose alcohol administration can address at least part of this problem. They can administer a precisely defined dose of alcohol and a placebo to the same person on different days, draw blood at the same time, and compare the biological response. In this case, changes that appear only after alcohol exposure provide a much more convincing indication of its immediate, short-term effect. This is why the researchers chose a randomized, crossover design. [6]

At the same time, the authors wanted to explore another aspect of the question: whether the baseline state of the body differs in young people with already established, more intense alcohol consumption patterns. To this end, the experiment included both light and heavier drinkers. Here, the causality is weaker because drinking habits were not randomly assigned, but this approach allows for the search for potential early biological traces of systematic alcohol exposure. [7]

How the experiment was conducted

Each participant visited the laboratory three times. In one session, they received a placebo, in the second, alcohol at a dose of 0.35 g/kg, and in the third, 0.60 g/kg. The order of conditions was determined randomly, and at least three days elapsed between visits. Before each experiment, participants were instructed to abstain from alcohol and cannabis for 48 hours and to eat or drink nothing but water for three hours before the visit. [8]

All sessions began between approximately 9 and 11 a.m. Half an hour before drinking, participants received a standardized food bar to ensure that conditions were as similar as possible between days. After the low dose, the average peak breath alcohol concentration was 0.034%, while after the moderate dose, it was 0.063%. The peak was reached after approximately 30 and 60 minutes, respectively. [9]

Blood was collected immediately before the drink, and then after one, two, three, and four hours. This allowed the researchers to see not just a single "before/after" point, but the time course of each biomarker. This design was particularly important, as some indicators changed significantly over time even after placebo. [10]

Ten pre-selected molecules were measured. They represented five functional areas: metabolic regulation, vascular and endothelial signaling, systemic inflammation, tissue remodeling, and neuroimmune processes. Therefore, the study was aimed not at diagnosing a single disease, but at identifying a systemic biological response to alcohol. [11]

What markers were studied?

Biomarker	Basic biological connection
Adiponectin	metabolism, insulin sensitivity
LCN2/lipocalin-2	metabolic and inflammatory signaling
Angiogenin	vascular function and remodeling
D-dimer	coagulation and degradation of fibrin
ICAM-1	endothelial activation and interaction of leukocytes with the vascular wall
sRAGE	regulation of AGE-RAGE signaling
MMP-7	tissue remodeling
MMP-9	extracellular matrix remodeling
hsCRP	systemic inflammatory marker
TREM2	immune signaling, including that associated with microglia

The participants were young and formally healthy.

The average age of all 32 participants was 25 years, with little difference between groups: 25.5 years for heavier drinkers and 24.3 years for lighter drinkers. Twenty-one participants were female and 11 were male. None had a chronic medical condition requiring ongoing medication, and people with serious mental disorders or other substance use disorders were not included in the experiment. [12]

The light drinking group reported an average of 2.0 alcoholic drinks per week, while heavier drinkers reported approximately 9.3 drinks per week. The number of drinks per day of consumption was approximately 2.1 and 3.4, respectively. The difference in weekly consumption was statistically significant, p<0.001. [13]

However, the category of heavy drinkers in this study does not imply decades of severe alcohol dependence. Among participants in this group, the average age of onset of regular heavy drinking was approximately 20.2 years, and the average duration was only 1.7 years. Thirteen of the 17 reported binge drinking at least once a week, but only four met the criteria for a mild alcohol use disorder, and severe alcohol use disorder was not present in the study group. [14]

It is this characteristic that makes the results interesting: potential biomarker differences were detected not in older adults with decades of alcohol exposure and established cirrhosis or cardiovascular disease, but in relatively healthy young adults. On the other hand, the small and selective sample means that these figures cannot be considered typical for all 25-year-olds who consume alcohol. [15]

Characteristic	Easy to use	More intense
Participants	15	17
Middle age	24.3 years	25.5 years
Drinks per week	2.0	9.3
Drinks per day consumed	2.1	3.4
History of regular heavy use >6 months	was absent	was present according to the study criteria
Average age of onset of heavy drinking	-	20.2 years
Average duration	-	1.7 years
Binge ≥1 time per week	-	13 of 17
Easy AUD	0	4 of 17

Five biomarkers differed in heavier drinkers

The first important finding was unrelated to what happened after the experimental drink. When data were pooled across lab sessions, heavier drinkers had, on average, higher levels of adiponectin, angiogenin, ICAM-1, LCN2, and sRAGE. For adiponectin, the p value was 0.034, for angiogenin it was less than 0.001, for ICAM-1 it was 0.003, for LCN2 it was 0.027, and for sRAGE it was 0.047. [16]

Of particular interest are angiogenin and ICAM-1. Both are associated with vascular biology. ICAM-1 is expressed on endothelial cells and helps leukocytes adhere to and penetrate the vascular wall during the inflammatory response. Elevations of these markers may indicate altered endothelial signaling even before the onset of clinically evident vascular disease. The authors, however, did not measure vascular function directly and therefore interpret this result as a potential early signal rather than definitive arterial damage. [17]

LCN2, or lipocalin-2, is associated with inflammatory and metabolic processes. Its elevated concentrations are found in various states of metabolic dysfunction. In young people who drink more heavily, the level was higher, which the authors consider further evidence that alcohol use patterns can be accompanied by restructuring of the metabolic and immune environment before the development of overt chronic disease. [18]

But there's a fundamental difference here from experimental dose effects. People weren't randomly assigned to "light" and "heavy" drinking groups. Therefore, scientists can't claim that heavier alcohol consumption directly caused the elevated levels of these five molecules. Even after accounting for similarity between groups in key demographic characteristics, there may be unaccounted for differences in diet, sleep, stress, physical activity, or other factors. The authors themselves explicitly refer to these differences as associations. [19]

What indicators differed between groups?

Marker	In heavier drinkers	p
Adiponectin	higher	0.034
Angiogenin	higher	<0.001
ICAM-1	higher	0.003
LCN2	higher	0.027
sRAGE	higher	0.047
D-dimer	there is no significant difference	-
TREM2	there is no significant difference	-

Elevated adiponectin cannot simply be called a bad marker.

One of the most unusual findings was higher adiponectin levels in the heavy drinking group. This adipose tissue hormone is typically perceived as metabolically beneficial: it is associated with improved insulin sensitivity and has a number of anti-inflammatory properties. Therefore, at first glance, its elevation doesn't seem to fit well with the idea of alcohol's early harm. [20]

However, the biological significance of a single biomarker depends on the context. Elevated adiponectin does not always indicate improved health, and in some conditions, a so-called "adiponectin paradox" is observed, where high adiponectin levels are accompanied by adverse processes. Therefore, the authors do not consider the detected increase to be evidence of metabolic damage.

A more cautious interpretation is that alcohol is capable of altering adipokine signaling. Previous controlled studies have also shown increases in circulating adiponectin after regular consumption of approximately 40 g of alcohol per day for several weeks. The new study is consistent with such observations but does not establish whether this response is protective, compensatory, or potentially detrimental. [21]

This is a good example of why it's impossible to simply take a list of five "altered" proteins and declare them five hallmarks of an incipient disease. Biomarkers indicate changes in system function, but the direction of clinical significance must be determined separately. The overall value of the result lies primarily in the fact that several independent body systems were already differentiated between the two groups of young, healthy individuals.

The clearest immediate effect of alcohol was found for sRAGE

SRAGE is a soluble form of the receptor for advanced glycation end products. Unlike membrane-bound RAGE, whose activation can enhance inflammatory signaling, soluble sRAGE is capable of binding circulating ligands, including advanced glycation end products and other proinflammatory molecules, thereby acting as a molecular decoy. Therefore, calling sRAGE simply a "proinflammatory protein" would be inaccurate. [22]

In all three experimental conditions, sRAGE concentrations initially decreased after an hour. After placebo, the decrease from baseline was statistically significant (p=0.009). A similar early decline occurred after both alcohol doses. The presence of placebo allowed us to understand that the initial decline was likely related not to ethanol, but to normal time, dietary, or other physiological fluctuations. [23]

The trajectories then diverged. After the low dose, sRAGE remained below baseline for the entire four hours. After 0.60 g/kg, the indicator, after an initial decline, increased again: between the first and second hours, p=0.002, and between the first and third, p=0.014. Ultimately, the statistical model revealed a significant interaction between dose and time, p=0.025. [24]

The authors suggest that this increase may represent a rapid compensatory response to increased inflammatory ligands or oxidative stress. However, this is speculative, as advanced glycation end products (AGEs) or direct indicators of oxidative damage were not measured simultaneously. Interestingly, baseline sRAGE was also higher in the habitually higher-dose group, suggesting a link between repeated short-term responses and more sustained system remodeling—however, longitudinal evidence for such a pattern is still lacking. [25]

SRAGE dynamics after drinking

Condition	1 hour	2-3 hours	General interpretation
Placebo	↓	returns closer to the original	probable normal time dynamics
0.35 g/kg	↓	remains reduced	differs from a moderate dose
0.60 g/kg	↓	then ↑	possible compensatory reaction
Dose x time	-	p=0.025	statistically significant interaction

What does sRAGE mean and why its rise alone is not a sign of illness?

The AGE-RAGE system is involved in chronic inflammation, endothelial dysfunction, diabetic complications, atherosclerosis, and age-related changes. Upon binding certain ligands, membrane-bound RAGE can activate intracellular inflammatory cascades. sRAGE, in contrast, circulates in the blood and can intercept some of these molecules before they interact with cellular receptors.

Therefore, both increases and decreases in sRAGE may have different meanings depending on the body's condition. Altered levels are found in people with diabetes, atherosclerosis, and other chronic inflammatory conditions, but sRAGE cannot be viewed as a simple linear "higher is worse" indicator. In some situations, an increase may reflect a protective compensatory response. [26]

In the new experiment, this compensatory explanation for the short-term increase after a moderate dose is the most plausible. The body may have increased the availability of the soluble receptor in response to the changed load of inflammatory ligands. However, the study does not show whether this response is sufficient for protection or, on the contrary, indicates stress that, with regular repetition, gradually becomes harmful.

The authors propose an interesting, but as yet unproven, model: repeated episodes of elevated sRAGE after alcohol consumption could potentially contribute to persistent dysregulation of the AGE-RAGE system over time. To test this hypothesis, studies are needed in which the same individuals are followed for months or years, simultaneously recording alcohol consumption and changes in biomarkers. [27]

A low dose lowered hsCRP - but that doesn't mean alcohol suppressed inflammation

In a laboratory analysis, high-sensitivity C-reactive protein levels were lower in the low-dose alcohol condition compared to placebo. Statistically, the result was convincing: the overall dose effect was p<0.001. At first glance, this could be interpreted as a rapid anti-inflammatory effect of a small dose of alcohol. [28]

However, the authors themselves specifically caution against this interpretation. C-reactive protein is synthesized relatively slowly by the liver. Its concentration is not able to adequately reflect the onset or resolution of systemic inflammation within a few hours after a single drink as quickly as some cytokines or cellular signals. [29]

Therefore, the decrease in hsCRP over a four-hour period is most likely due to short-term physiological processes—for example, the redistribution of the substance between compartments or changes in plasma concentration—rather than the fact that alcohol has managed to suppress the synthesis of the inflammatory protein in the liver. The temporal physiology of the marker is more important here than the p-value itself.

This result is particularly important for the popular myth of "a little bit of alcohol is good for you." The new study provides no evidence that a low dose of alcohol has anti-inflammatory or cardiovascular benefits. On the contrary, the authors explicitly point out that the hsCRP effect cannot be interpreted as a rapid suppression of inflammation. [30]

Some "post-alcohol changes" turned out to be normal body fluctuations

LCN2, MMP-7, and MMP-9 changed significantly over the four-hour observation period. LCN2 decreased in the first one to two hours, MMP-7 decreased after an hour, while MMP-9 gradually increased. If the study had included only the alcohol day without a placebo, such dynamics could easily be mistakenly attributed to the effects of alcohol. [31]

However, statistical analysis showed that these changes occurred regardless of what the person drank. They were observed with placebo, low, and moderate doses, and were not affected by light or heavy drinking. This indicates normal intraday dynamics.

Possible causes include circadian rhythms and the response to a standardized meal. All laboratory visits began in the morning and ended in the afternoon, so the researchers observed people during approximately the same physiological time window. MMPs and lipocalins can change throughout the day, independent of alcohol. [32]

For biomarker studies, this is a methodologically important result in itself. A simple "measure before a drink and three hours later" approach can lead to a false conclusion about the alcohol effect. Placebo control is necessary because some apparent biological responses actually represent normal temporal or postprandial variability. [33]

Marker	What happened?	Is it directly related to alcohol?
LCN2	↓ in 1-2 hours	no, the general effect of time
MMP-7	↓ in 1 hour	no, the general effect of time
MMP-9	↑ during observation	no, the general effect of time
D-dimer	there are no significant changes	No
TREM2	there are no significant changes	No
sRAGE	dose and time dependence	Yes, an acute alcohol effect is possible.
hsCRP	lower at low dose	There is an association with the condition, but the mechanism does not correspond to the rapid suppression of inflammation

Why are elevated ICAM-1 and angiogenin of interest to blood vessels?

ICAM-1 is a cell adhesion molecule expressed, in particular, by endothelial cells. It helps immune cells adhere to the vascular wall and migrate into the tissue during inflammation. Increased endothelial expression of ICAM-1 is involved in the early stages of atherosclerosis, although the concentration of soluble ICAM-1 in the blood alone is not a diagnostic test for atherosclerosis.

Angiogenin is involved in vascular formation, cellular stress, and tissue remodeling. Its levels change in various cardiovascular, inflammatory, and oncological diseases, but it is also a nonspecific protein. Therefore, an increase in two vascular-related molecules simultaneously in heavier drinkers appears biologically more interesting than a change in a single laboratory variable. [34]

The authors suggest that this profile may reflect the early activation of endothelial and vascular signaling pathways long before the onset of clinical disease. This is consistent with broader evidence on alcohol's ability to promote endothelial dysfunction, oxidative stress, and adverse vascular remodeling.

However, the new study did not include ultrasound tests of endothelial function, coronary calcium measurements, or vascular imaging. Therefore, it cannot be concluded that the 25-year-old participants already had atherosclerosis. This is only a study of laboratory signals associated with vascular biology in other studies.

TREM2 and D-dimer are unchanged – and that's important too

D-dimer is a fibrin breakdown product and is widely used in clinical practice, for example, to rule out venous thrombosis and pulmonary embolism in the appropriate clinical context. In the new experiment, the researchers found no significant effect of either the drinking group, alcohol dose, or time on D-dimer. [35]

This means that the doses studied did not cause measurable systemic changes in this coagulation marker over four hours. However, this does not mean that alcohol has no effect on thrombosis or hemostasis at all. Other doses, prolonged exposure, and other components of the coagulation system could have different effects.

TREM2 has been studied as an indicator associated with myeloid cells and neuroimmune signaling. Despite experimental evidence for a role for TREM2 in the brain's response to alcohol, no significant effects were found in peripheral plasma in the new study. [36]

The authors specifically note that TREM2 concentrations in the blood may poorly reflect what's happening directly in the brain. The lack of change in the peripheral marker therefore does not rule out the possibility of a neuroimmune effect of alcohol. Therefore, they suggest combining blood analysis with neuroimaging and multi-omics methods as future research. [37]

Previously, these same participants had already been found to have a different immune response to alcohol.

The current study is a continuation of the same sample and experimental protocol. In 2025, Monnig and colleagues published the results of an analysis of other markers—bacterial translocation, macrophage activation, and inflammatory cytokines. DOI of the previous work is 10.1111/acer.70106. [38]

Then, heavier drinkers showed different immune responses, including higher levels of the macrophage activation marker sCD163. Short-term changes in IL-8, TNF-α, and IL-6 were also observed after experimental alcohol consumption, with the nature of the response partly dependent on habitual drinking patterns. [39]

Together, the two studies paint a broader picture. In people with heavier alcohol consumption, markers of macrophages, endothelium, metabolic and inflammatory signaling simultaneously differed, whereas a single dose of alcohol elicited rapid but unequal responses from individual systems. The authors call this a possible change in the "biological baseline," or allostatic setpoint. [40]

However, a previous study did not detect a rapid increase in bacterial lipopolysaccharide in the blood after the doses studied. Therefore, the immune effects observed in the first four hours are likely not explained by a sharp disruption of the intestinal barrier. It is possible that at 0.35-0.60 g/kg, the body of young, healthy individuals is still quite effective in preventing such translocation, while more pronounced disturbances appear with higher or repeated doses. [41]

Does the study prove that nine drinks a week already causes chronic disease?

No. This is one of the most important points for correct interpretation. The study did indeed identify five statistically different biomarkers between the light and heavier drinking groups, but the distribution of people into these categories was not randomized. Therefore, it is impossible to causally attribute these chronic differences solely to alcohol. [42]

Individual risk for disease cannot be determined from the reported average of 9.3 drinks per week. Participants were classified based on a broader drinking history and NIAAA criteria, including episodes of binge drinking. Thirteen of the 17 in the more intense group reported such episodes at least once a week, so the average weekly number does not fully describe the pattern of exposure. [43]

The study did not observe heart attacks, strokes, diabetes, cancer, or dementia. It measured molecules that have been linked to relevant physiological processes in other studies. Therefore, the statement "chronic disease markers were detected in young drinkers" requires clarification: changes in biomarkers associated with chronic disease mechanisms were detected, not laboratory signs of pre-existing diabetes or atherosclerosis. [44]

Nevertheless, the age of the participants makes the signal scientifically interesting. If the differences are replicated in larger studies and are found to progress with duration of use, this could indicate that molecular reorganization begins significantly earlier than the onset of clinical symptoms.

Does the experiment prove that even one small dose of alcohol is dangerous?

No, that's not true. The experiment allows for a fairly reliable assessment of the short-term response of individual biomarkers to a strictly defined dose, because each person served as their own control and received a placebo. But it did not measure the actual medical consequences of a single alcohol intake. [45]

At the low dose, hsCRP and sRAGE time courses differed from placebo. However, the authors themselves emphasize that the decrease in hsCRP does not correspond to the time course of a true rapid anti-inflammatory effect. The significance of the change in sRAGE is also ambiguous.

The clearest acute signal emerged after the higher dose of 0.60 g/kg: after an initial decrease common to all conditions, sRAGE began to increase again. This is consistent with a dose-dependent response, but it is not yet known whether this transient change is directly damaging, neutral, or compensatory-protective. [46]

Therefore, this study better answers the question "Can alcohol rapidly alter a person's biological signaling?"—yes, it can. It does a much worse job of answering the question "How much does one specific dose increase the risk of disease over ten years?"—for that, completely different research is needed.

Why placebo was one of the study's greatest strengths

In nutrition and alcohol studies, it's common to take blood samples before and several hours after drinking. If a reading changes, the researcher might be tempted to attribute the change to the drink. But the body is constantly changing, even at rest.

For example, in the current study, sRAGE decreased within an hour even after placebo. LCN2, MMP-7, and MMP-9 also changed regardless of alcohol content. Without a control day, all of these effects could easily be mistakenly attributed to the effects of ethanol. [47]

The causes include circadian fluctuations, food intake, stress from the laboratory procedure, changes in body position, and a host of other physiological factors. Blood was collected during the morning and afternoon hours, so some molecules naturally underwent different phases of their daily dynamics.

The crossover design further reduces the influence of interindividual variability. One person may initially have twice the level of a particular protein as another, but since each participant received all three drinks, the researchers could compare them primarily to themselves. For a small study of 32 people, this significantly increases statistical power.

Main limitations of the study

The main limitation is obvious: only 32 participants. This sample size allows for the detection of fairly large changes, especially in a cross-sectional design, but easily misses weaker effects. It also makes it virtually impossible to reliably examine differences between men and women, racial or ethnic groups, and other subgroups. [48]

The second limitation is the four-hour observation period. Some immune mediators respond within minutes or hours, but other biomarkers require significantly longer. hsCRP is a good example: the physiological kinetics of its synthesis make a four-hour period too short to interpret the change as a full-fledged inflammatory response. [49]

Third, blood, not organs, was analyzed. Plasma biomarkers provide a scalable picture of systemic physiology, but do not directly reveal what is happening in the brain, liver, artery wall, or adipose tissue. The authors specifically cite TREM2 as an example of how the lack of an effect in plasma does not exclude tissue-specific changes in the central nervous system. [50]

Finally, the differences between habitual light and heavier drinkers are cross-sectional associations. The researchers only assigned single doses, not drinking history, experimentally. Furthermore, ten biomarkers were analyzed, and although Sidak's correction for pairwise comparisons was applied within individual models, no additional overall correction was applied across the entire set of models. This increases the need for independent replication of the results. [51]

What limits the conclusions

Limitation	Practical significance
N=32	small sample
15 versus 17 people	unstable estimates of intergroup differences
Observation 4 hours	late reactions cannot be assessed
Young healthy adults only	Tolerability to the elderly and sick is unknown
Plasma biomarkers	do not directly show changes in organs
Drinking status is not randomized	chronic causality has not been proven
10 markers	risk of random statistical findings
There are no long-term outcomes	the risk of heart attack, cancer or diabetes cannot be calculated
Only two doses of alcohol	the full dose-response range is missing

What the researchers propose to study further

The first necessary step is to replicate the experiment in a significantly larger and more diverse sample. This will allow us to test whether the differences in adiponectin, angiogenin, ICAM-1, LCN2, and sRAGE are reproducible, and to determine whether the responses differ by gender, age, race, and ethnicity. [52]

The second approach is to increase the duration of observation after alcohol consumption. Four hours is sufficient for rapid signaling molecules, but insufficient for many endocrine, inflammatory, and metabolic processes. The authors also propose using a wider range of doses to determine the amount of alcohol at which signs of intestinal barrier disruption and other later effects appear. [53]

The third goal is to combine blood with neuroimaging and multiomics. Analysis of the transcriptome, proteome, metabolome, and other molecular layers will allow us to link circulating biomarkers to specific cellular programs. This is especially important for the brain, where plasma TREM2 does not necessarily reflect microglial activity. [54]

Finally, longitudinal studies are needed. These are the ones that should show whether short-term changes in sRAGE persist after repeated episodes of use, whether they accumulate, and whether they develop into stable dysregulation over time. Without such a step, it is impossible to build a reliable bridge from a few hours of laboratory experiment to chronic disease decades later. [55]

How the study changes our understanding of alcohol

The study did not find a single, universal "marker of alcohol harm." Instead, the results demonstrate how heterogeneous the physiological response is. Some indicators varied between individuals with different drinking histories, another—sRAGE—responded quickly to a specific dose, and others changed over time completely independent of alcohol. [56]

This supports the systems model, which posits that the effects of alcohol arise not from a single inflammatory pathway, but from the interaction of metabolic, vascular, immune, and tissue signaling. Even small changes in each pathway may not be harmful in themselves, but the regular repetition of several disruptions could theoretically shift the physiological balance over time.

Particularly noteworthy is that some group differences emerged in individuals with an average age of only 25 years and a relatively short history of more intense use. This is not yet a chronic disease, but potentially an early stage of biological adaptation. The authors describe this pattern as a possible development of an altered allostatic state—a new "basic setting" for the body after repeated exposure. [57]

At the same time, the study highlights the dangers of overly simplistic conclusions. A decrease in hsCRP does not necessarily indicate a proven benefit from a small dose of alcohol; elevated sRAGE does not necessarily indicate direct harm; and high adiponectin is not necessarily definitively bad. The entire profile and its dynamics are important, not a single indicator isolated from its biological context.

The main conclusion

In a controlled experiment in 32 young healthy adults, alcohol induced a dose-dependent change in sRAGE, and the low experimental dose was associated with lower measured hsCRP concentrations compared to placebo. However, the authors specifically caution that the four-hour change in hsCRP is too rapid to conclude that a true anti-inflammatory effect exists. [58]

Even more interesting were the differences that existed regardless of the experimental drink. Young people with more intense drinking patterns had higher levels of five markers—adiponectin, angiogenin, ICAM-1, LCN2, and sRAGE. These reflect various aspects of metabolic, vascular, and inflammatory signaling. [59]

However, experimental causality can only be confidently discussed for short-term exposure to a randomly assigned dose of alcohol. Drinking history was not randomized, so differences between light and heavier drinkers are still purely inferred. The study also does not indicate that participants already have cardiovascular disease, diabetes, dementia, or other chronic conditions. [60]

Thus, the primary significance of this study is that it reveals early, multisystemic biological changes associated with alcohol consumption in young, clinically healthy individuals. The next question, far more important, is whether these short-term, early changes, when repeated over many years, develop into stable mechanisms of chronic disease. The current study does not yet provide an answer.

News source

Monnig MA, Clark SE, Monti PM Effects of Acute Low- and Moderate-Dose Alcohol on Chronic Disease-Related Biomarkers in Healthy Light and Heavy Drinkers. Alcohol: Clinical and Experimental Research. 2026;50(9):e70362. Article first published September 7, 2026. DOI: 10.1111/acer.70362.

This is an original study with a randomized, placebo-controlled, crossover experimental design. It is important to distinguish between two sets of findings: the immediate response to alcohol dose was studied experimentally, while the comparison of habitual light and heavier drinkers based on baseline biomarkers remains observational.

The trial is registered with ClinicalTrials.gov under number NCT03483389. The work was funded by the National Institute on Alcohol Abuse and Alcoholism and the National Institute of General Medical Sciences of the US National Institutes of Health. The authors declare no conflicts of interest.

A related previous publication from the same research group and the same experimental sample on immune markers:

Monnig MA, Lamb PS, Clark SE, Monti PM Acute Changes in Immune Biomarkers Under Low- and Moderate-Dose Alcohol in Light and Heavy Drinkers: A Randomized, Placebo-Controlled Trial. Alcohol: Clinical and Experimental Research. 2025;49:1644-1658. DOI: 10.1111/acer.70106.